Aurinia Pharmaceuticals (AUPH) Retained Earnings (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Retained Earnings data on file, last reported at -$880000.0 in Q1 2026.

• Quarterly Retained Earnings rose 99.9% year-over-year to -$880000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$880000.0 (up 99.9% YoY) and the FY2025 annual result came in at -$649.4 million, up 30.67% from the prior year.
• Retained Earnings improved to -$880000.0 in Q1 2026, from -$649.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$749000.0 in Q3 2025 to a low of -$952.3 million in Q2 2024.
• A 5-year average of -$614.4 million and a median of -$838.3 million in 2022 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 99.92% in 2025, down 106835.13% in 2025.
• Tracing AUPH's Retained Earnings over 5 years: stood at -$864.3 million in 2022, then retreated by 9.03% to -$942.3 million in 2023, then rose by 0.61% to -$936.6 million in 2024, then jumped by 30.67% to -$649.4 million in 2025, then jumped by 99.86% to -$880000.0 in 2026.
• The last three Retained Earnings figures came in at -$880000.0 (Q1 2026), -$649.4 million (Q4 2025), and -$749000.0 (Q3 2025), per Business Quant data.